| Mangiferin (MGF) — Naturally occurring C-glucosyl xanthone found predominantly in Mangifera indica (mango) and several other medicinal plants. Mangiferin exhibits antioxidant, anti-inflammatory, metabolic, neuroprotective, immunomodulatory, and anticancer activities through modulation of multiple signaling pathways.
Cancer relevance: Strong preclinical evidence. Mangiferin has demonstrated antiproliferative, pro-apoptotic, anti-invasive, antimetastatic, and anti-angiogenic activity in breast, lung, liver, ovarian, prostate, gastric, colorectal, oral, hematologic, and other cancer models. Reported mechanisms include NF-kB ↓, PI3K/AKT ↓, MAPK signaling modulation, beta-catenin signaling ↓, EMT ↓, MMP2/MMP9 ↓, proliferation ↓, angiogenesis ↓, and apoptosis ↑. Mangiferin may also enhance sensitivity to selected chemotherapy drugs.
Alzheimer’s disease / neurodegeneration relevance: Primarily preclinical but substantial. Mangiferin has demonstrated neuroprotective and anti-neuroinflammatory activity in experimental neurodegenerative models. Reported mechanisms include oxidative stress ↓, NF-kB ↓, NLRP3 inflammasome ↓, inflammatory cytokines ↓, Nrf2/ARE signaling ↑, mitochondrial protection, and modulation of PI3K/AKT signaling.
Typical target/pathway effects: NF-kB ↓; NLRP3 ↓; inflammatory cytokines ↓; oxidative stress ↓ in non-cancer tissues; Nrf2 signaling ↑; PI3K/AKT modulation; beta-catenin ↓ in selected cancer models; MMP2 ↓; MMP9 ↓; EMT ↓; angiogenesis ↓; proliferation ↓; apoptosis ↑.
Bioavailability: Oral bioavailability is limited by poor aqueous solubility, intestinal absorption, and rapid metabolism. Nanoparticle, formulation, and structural-modification approaches have been investigated to improve systemic exposure.
Human evidence: Limited compared with the extensive in vitro and animal literature. Clinical translation remains insufficient to establish mangiferin as a treatment for cancer or Alzheimer’s disease.
Mangiferin — A naturally occurring polyphenolic C-glucosyl xanthone, chemically 1,3,6,7-tetrahydroxyxanthone-C2-β-D-glucoside, occurring prominently in Mangifera indica (mango) leaves, bark, peel and kernels and in several other medicinal plants. It is classified as a natural-product compound/xanthone glycoside and is commonly abbreviated MGF. Mangiferin is a pleiotropic bioactive molecule with antioxidant and cytoprotective actions in normal tissues but antiproliferative, pro-apoptotic, anti-invasive and chemosensitizing effects in numerous experimental cancer models. Its signaling effects are strongly cell- and disease-context dependent.
Primary mechanisms (ranked):
- Suppression of NIK/IKK/NF-κB survival and inflammatory signaling, reducing anti-apoptotic proteins such as XIAP, survivin and Bcl-xL.
- Suppression of PI3K/AKT/mTOR signaling in several cancer models, promoting apoptosis and inhibiting proliferation; this axis can be activated rather than suppressed in stressed normal cells.
- Induction of intrinsic apoptotic and cell-cycle programs, including caspase-3/-9 activation, Bax/Bad predominance and CDK1/cyclin-B1 inhibition.
- Suppression of β-catenin, EMT and matrix metalloproteinase signaling, reducing migration, invasion and metastatic potential.
- Metabolic inhibition in selected tumors, including PFKFB3-dependent glycolysis suppression and downstream PI3K/AKT/mTOR inhibition.
- Anti-angiogenic signaling through suppression of NF-κB-regulated VEGF/VEGFR and related invasive mediators in selected tumor models.
- Chemosensitization to agents including cisplatin, oxaliplatin, doxorubicin, melphalan and vincristine in preclinical models.
- Secondary redox modulation: NRF2/antioxidant signaling and ROS suppression are prominent protective mechanisms in normal or injured tissues; cancer-cell redox effects are model-dependent and should not be generalized as a simple ROS increase or decrease.
Bioavailability / PK relevance: Oral bioavailability is poor because of low aqueous solubility, limited intestinal absorption and extensive metabolism. In healthy humans, a very large 900-mg oral dose produced a reported peak plasma concentration of only about 38.6 ng/mL, approximately 0.09 µM, with an apparent elimination half-life of about 7.9 hours. Formulation materially affects exposure; a water-soluble mangiferin monosodium formulation produced approximately 2.4-fold greater systemic exposure than a poorly soluble mango-leaf extract in a human crossover PK study. Nanoparticles, liposomes, micelles, salts and other delivery systems remain investigational approaches to improve exposure.
In-vitro vs systemic exposure relevance: Many anticancer experiments use mangiferin concentrations in the approximately 5–100 µM range. These commonly exceed measured circulating concentrations after conventional oral mangiferin by one to several orders of magnitude. For example, gastric cancer IC50 values of approximately 4.8–16 µM remain roughly 50–175-fold above the approximately 0.09 µM human Cmax reported after 900 mg orally. Consequently, direct translation of standard in-vitro anticancer concentrations to conventional oral supplementation is uncertain.
Clinical evidence status: Cancer: preclinical, with cell-culture and multiple animal/xenograft studies but no established human anticancer efficacy. Alzheimer’s disease: preclinical, including APP/PS1 and other cognitive-impairment models, but no demonstrated clinical efficacy in AD. Human evidence includes pharmacokinetic studies and randomized studies in non-cancer settings such as hyperlipidemia and studies of standardized mango-leaf extracts in healthy subjects. Mangiferin is not an established or approved treatment for cancer or Alzheimer’s disease.
Mangiferin Cancer Mechanisms
| Rank |
Pathway / Axis |
Cancer Cells |
Normal Cells |
Primary Effect |
Notes / Interpretation |
| 1 |
NIK / IKK / NF-κB survival signaling |
↓ NIK, ↓ NF-κB nuclear signaling, ↓ XIAP, ↓ survivin, ↓ Bcl-xL |
↓ excessive NF-κB activation (context-dependent) |
Apoptosis ↑; inflammatory survival signaling ↓ |
One of the most reproducible anticancer axes; demonstrated in leukemia, myeloma, melanoma and other models. |
| 2 |
PI3K / AKT / mTOR |
↓ p-PI3K, ↓ p-AKT, ↓ p-mTOR (model-dependent) |
↑ PI3K/AKT can occur during cytoprotection |
Proliferation ↓; apoptosis ↑ |
Strong cancer evidence in gastric carcinoma and glioblastoma. Direction is tissue-dependent and should not be generalized to normal cells. |
| 3 |
Apoptosis and cell-cycle control |
↑ Bax/Bad, ↑ caspase-3/-9, ↓ Bcl-2/Bcl-xL/Mcl-1, ↓ CDK1/cyclin B1 |
↓ stress-induced apoptosis in several injury models |
Intrinsic apoptosis ↑; cell-cycle arrest ↑ |
Cancer-selective direction differs substantially from mangiferin's frequently cytoprotective behavior in non-malignant tissues. |
| 4 |
β-Catenin / EMT / MMP invasion axis |
↓ active β-catenin, ↓ MMP-7/-9, ↓ vimentin, ↑ E-cadherin |
↔ (context-dependent) |
Migration ↓; invasion ↓; metastasis ↓ |
Supported by breast-cancer cell and xenograft experiments. |
| 5 |
PFKFB3 / Glycolysis |
↓ PFKFB3, ↓ glycolytic flux, ↓ PI3K/AKT/mTOR |
Not established |
Tumor metabolism ↓; proliferation ↓ |
Strong recent mechanistic evidence in glioblastoma; currently tumor/model-specific rather than a universal mangiferin mechanism. |
| 6 |
Angiogenesis / VEGF signaling |
↓ VEGFR2 and NF-κB-regulated angiogenic mediators |
↔ or ↑ reparative angiogenesis (context-dependent) |
Tumor angiogenesis ↓ |
Anti-angiogenic activity demonstrated particularly in melanoma models. Mangiferin can support angiogenesis in metabolically stressed normal endothelium, emphasizing context dependence. |
| 7 |
Chemosensitization |
↑ chemotherapy response; ↓ NF-κB survival signaling; ↓ P-gp in selected models |
↔; cytoprotection may occur in some normal tissues |
Drug sensitivity ↑ |
Preclinical sensitization reported with cisplatin, oxaliplatin, doxorubicin, melphalan and vincristine. No established clinical combination regimen. |
| 8 |
Mevalonate / Proteasome / Plasmin |
↓ HMG-CoA reductase activity, ↓ proteasome activity, ↓ plasmin-mediated migration |
Not established |
Proliferation ↓; migration ↓; apoptosis ↑ |
Demonstrated in breast-cancer models; mechanistically interesting but less broadly replicated than NF-κB or PI3K/AKT effects. |
| 9 |
NRF2 / ROS redox modulation |
↔ ROS and NRF2 (model-dependent) |
↑ NRF2, ↑ antioxidant defenses, ↓ pathological ROS |
Normal-tissue cytoprotection; cancer effects variable |
NRF2 activation and ROS suppression are better established as protective actions in normal or injured tissues than as a universal anticancer mechanism. |
| 10 |
Clinical Translation Constraint |
Poor oral exposure relative to many experimental concentrations |
Human systemic exposure remains low |
Translation limited |
Low solubility and absorption, extensive metabolism, formulation dependence and absence of oncology efficacy trials are major constraints. |
Alzheimer’s disease relevance: Mangiferin has meaningful but entirely preclinical relevance to Alzheimer’s disease and related neurodegenerative mechanisms. Oral treatment improved memory and reduced tau pathology, neuroinflammation and neuronal structural abnormalities in APP/PS1 mice, although amyloid burden was not significantly reduced in that model. Newer experimental work supports suppression of tau hyperphosphorylation through PI3K/AKT-mediated inhibition of GSK3β, together with inhibition of microglial NF-κB/NLRP3 signaling and AMPK/mTOR/IRF5-mediated neuroinflammation. Mangiferin also reduces oxidative stress, calcium overload, mitochondrial dysfunction and endoplasmic-reticulum stress in experimental neurotoxicity models. These findings do not yet establish prevention or treatment of human AD.
Clinical translation: No convincing human trial evidence demonstrates disease modification, cognitive benefit in Alzheimer’s disease, or reduction of amyloid/tau pathology. Human studies of mango-leaf extracts in healthy adults cannot be extrapolated to AD treatment.
Mangiferin Alzheimer’s Disease Mechanisms
| Rank |
Pathway / Axis |
Modulation |
Primary Effect |
Notes / Interpretation |
| 1 |
PI3K / AKT / GSK3β / Tau |
↑ PI3K/AKT, ↑ inhibitory GSK3β Ser9 phosphorylation, ↓ Tau hyperphosphorylation |
Tau pathology ↓; neuronal survival ↑ |
Supported by 2026 mouse experiments; illustrates the opposite PI3K/AKT direction from that observed in several cancer models. |
| 2 |
Microglial NF-κB / NLRP3 |
↓ NF-κB, ↓ NLRP3, ↓ IL-1β, ↓ IL-6, ↓ TNF-α |
Neuroinflammation ↓ |
Supported principally by experimental microglial and neuroinflammation models. |
| 3 |
Tau pathology and neurodegeneration |
↓ Tau hyperphosphorylation; ↓ neuronal dystrophy |
Neuronal integrity ↑; cognition ↑ |
Long-term treatment improved memory and tau-related pathology in APP/PS1 mice without significantly reducing amyloid burden. |
| 4 |
AMPK / mTOR / IRF5 |
↑ AMPK, ↓ mTOR, ↓ IRF5 |
Microglial activation ↓; neuronal senescence ↓ |
Recent experimental evidence links this axis to reduced Aβ-associated inflammatory neuronal senescence. |
| 5 |
ER stress / Ca²⁺ / Mitochondria |
↓ GRP78, ↓ CHOP, ↓ Ca²⁺ overload, ↓ mitochondrial dysfunction |
Neurotoxicity ↓ |
Demonstrated in formaldehyde-induced neuronal injury and cognitive-impairment models. |
| 6 |
ROS / NRF2 antioxidant defense |
↓ pathological ROS, ↑ antioxidant signaling |
Oxidative injury ↓ |
Consistent with the broader cytoprotective pharmacology of mangiferin in non-malignant tissues. |
| 7 |
Clinical Translation Constraint |
Poor oral bioavailability; no AD efficacy trials |
Clinical significance uncertain |
Animal cognitive improvements cannot currently be translated into a recommended human AD dose or therapeutic effect. |
|